新诊断和干扰素治疗失败的慢性髓性白血病患者应用伊马替尼治疗的效果  

The efficacy of imatinib treatment in patients with newly diagnosed and interferon-treated chronic myeloid leukemia

作　　者：彭毅[1] Peng Yi(Hubei Aerospace Hospital,Xiaogan,Hubei,432000,China)

机构地区：[1]湖北航天医院,湖北孝感432000

出　　处：《当代医学》2018年第13期17-19,共3页Contemporary Medicine

摘　　要：目的分析新诊断和干扰素治疗失败的慢性髓性白血病患者应用伊马替尼治疗的效果。方法选取2011年1月~2015年1月本院收治的慢性髓性白血病患者中选取100例,其中有50例为新诊断的慢性髓性白血病患者(甲组),50例为重组人干扰素α-2b治疗失败的慢性髓性白血病患者(乙组),两组患者均采用伊马替尼对进行治疗,分析两组患者的临床疗效。结果两组患者经过24个月的治疗后,甲组中有47例患者获得部分细胞学反应,比例为94%,乙组中有46例,比例为92%,差异无统计学意义;经过6个月治疗后,甲组中有82%(41/50)患者获得部分细胞学反应显著高于乙组患者的26%(13/50);甲组中有86%(43/50)患者获得完全细胞学反应高于乙组的68%(34/50);甲组70%(35/50)患者获得完全分子生物学反应高于对照组的40%(20/50),差异有统计学意义(P<0.05);相较于甲组,乙组患者的伊马替尼的耐药率更高,差异有统计学意义(P<0.05);两组患者经过治疗后,获得了类似的非血液学和血液学毒副作用,水钠潴留为其主要表现;相较于甲组,乙组患者白细胞减少率与Ⅲ~Ⅳ级贫血率更高,差异有统计学意义(P<0.05)。结论相较于干扰素治疗失败的慢性髓性白血病患者,新诊断的慢性髓性白血病患者采用伊马替尼进行治疗的效果更加显著,而干扰素治疗失败的慢性髓性白血病患者应该及时采用第二代酪氨酸激酶抑制剂进行治疗。Objective To analyze the efficacy of imatinib treatment in patients with chronic myeloid leukemia treated with new diagnosis and interferon therapy.Methods 100 cases of patients with chronic myelogenous leukemia were selected from January 2011 to January 2011 in our hospital,including 50 cases of newly diagnosed patients with chronic myelogenous leukemia(first group),50 cases of human recombinant interferonα-2 b treatment failure patients with chronic myelogenous leukemia(second group),both groups were treated with imatinib and analyzed the clinical efficacy.Results After 24 months of treatment in both groups,47 patients in first group received some cytological responses,and the proportion was 94%.In second group,there were 46 cases,with a proportion of 92%,and the difference was not statistically significant.After 6 months of treatment,82%(41/50)of the patients in the first group received some cytological response significantly higher than the 26%(13/50)of the patients in second group.In first group,86%(43/50)of the patients received complete cytological response higher than 68%(34/50)of second group;In first group 70%(35/50),the total molecular biological response was higher than 40%(20/50)in the second group,and the difference was statistically significant(P<0.05).Compared with first group,the resistance rate of imatinib in second group was higher,and the difference was statistically significant(P<0.05).After treatment,two groups of patients were treated with similar non-hematology and hematological side effects,and water sodium retention was the main performance.Compared with first group,the rate of leucocyte reduction in second group was higher than that in the patients with higher level of blood loss,and the difference was statistically significant(P<0.05).Conclusion Compared with interferon treatment failure patients with chronic myelogenous leukemia,newly diagnosed patients with chronic myelogenous leukemia with imatinib therapy effect is more significant,and the failure of interferon in treating chronic

关 键 词：新诊断 干扰素 慢性髓性白血病 伊马替尼 

分 类 号：R733.72[医药卫生—肿瘤]